Stockscreener 앱 받기
740.93
0.23%
-2.42
전일 마감가:
$743.35
열려 있는:
$744.87
하루 거래량:
95,563
Relative Volume:
0.15
시가총액:
$81.65B
수익:
$13.85B
순이익/손실:
$4.65B
주가수익비율:
21.13
EPS:
35.06
순현금흐름:
$3.32B
1주 성능:
-5.22%
1개월 성능:
-23.42%
6개월 성능:
-25.38%
1년 성능:
-7.16%
1일 변동 폭
$735.95
$746.86
1주일 범위
$735.95
$783.10
52주 변동 폭
$735.95
$1,211.20
리제네론 파마슈티컬스 Stock (REGN) Company Profile
명칭
Regeneron Pharmaceuticals Inc
전화
(914) 847-7000
주소
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
REGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| REGN | 740.00 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| VRTX | 446.78 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| ARGX | 588.98 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.89 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 104.15 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
리제네론 파마슈티컬스 Stock (REGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-01-12 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-03 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | 재확인 | Oppenheimer | Perform |
| 2023-06-28 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-03-23 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2023-01-20 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-10-26 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-09-09 | 업그레이드 | Jefferies | Underperform → Hold |
| 2022-09-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-06-06 | 개시 | Jefferies | Underperform |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-01-05 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-01-03 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-12-07 | 재개 | Cowen | Market Perform |
| 2021-12-06 | 개시 | Goldman | Buy |
| 2021-11-19 | 재개 | BMO Capital Markets | Outperform |
| 2021-11-05 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-06-29 | 개시 | H.C. Wainwright | Buy |
| 2021-01-25 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-01-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-10-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2020-07-09 | 업그레이드 | SunTrust | Hold → Buy |
| 2020-05-26 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-04-17 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2020-04-08 | 개시 | The Benchmark Company | Hold |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-02-26 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-11 | 업그레이드 | Argus | Hold → Buy |
| 2019-12-24 | 개시 | Raymond James | Mkt Perform |
| 2019-12-16 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-12-13 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | 개시 | SunTrust | Hold |
| 2019-11-07 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
모두보기
리제네론 파마슈티컬스 주식(REGN)의 최신 뉴스
Connor Clark & Lunn Investment Management Ltd. Has $21.56 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
B. Metzler seel. Sohn & Co. Holding AG Buys New Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
(REGN) On The My Stocks Page - Stock Traders Daily
Multiple Myeloma Market on Track for Major Expansion by 2034, According to DelveInsight | Janssen Pharma, Regeneron Pharma, Johnson & Johnson Innovative Medicine, Bristol Myers Squibb, Regeneron - Barchart
Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Myopic Macular Degeneration Market Forecasted to Surge - openPR
Retireful LLC Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Multiple Myeloma Market on Track for Major Expansion by 2034, - openPR
Breakthrough Therapy BT Designation Market Is Booming - openPR
Artery Stenosis Drug Market Insights Comprehensive Trends, - openPR
Retinal Biologics Market: Future Scope, Growth Potential, - openPR
Regeneron Pharmaceuticals, Inc. (REGN): Among the Best Genomics Stocks to Buy Right Now - Insider Monkey
Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Regeneron: The Biotech Stock To Buy Now (NASDAQ:REGN) - Seeking Alpha
Eczema Therapeutics Market 2024-2031 Revenues Will Increase - openPR
10 Best Genomics Stocks To Buy Right Now - Insider Monkey
Regeneron Pharmaceuticals's Options: A Look at What the Big Money is Thinking - Benzinga
Here’s Why Regeneron Pharmaceuticals (REGN) Declined in Q3 - Insider Monkey
Familial Hypercholesterolemia Market Forecasted to Surge - openPR
Quest Partners LLC Boosts Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Macular Degeneration Treatment Market Is Expected To Reach - openPR
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
10 Biggest Biotechnology Companies - Investopedia
FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria - Nasdaq
Regeneron Says Samsung Eye Med Biosimilar Will Infringe IP - Law360
Peering Into Regeneron Pharmaceuticals's Recent Short Interest - Benzinga
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Braun Stacey Associates Inc. - MarketBeat
Cutaneous Squamous Cell Carcinoma Market Geographical - openPR
2 Top Growth Stocks to Buy on the Dip - AOL
Swiss National Bank Acquires 2,000 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Seizert Capital Partners LLC - MarketBeat
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis - GlobeNewswire Inc.
Mizuho Securities USA LLC Acquires 51,162 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by CIBC Asset Management Inc - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Wolfe Research - MarketBeat
Rep. Greg Landsman Sells Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock - MarketBeat
Citigroup Initiates Coverage of Regeneron Pharmaceuticals (REGN) with Neutral Recommendation - MSN
Regeneron to “vigorously defend” against DOJ on Eylea pricing complaint - MSN
Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria - Pharmaceutical Technology
Simplify Asset Management Inc. Purchases 3,231 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Check Out What Whales Are Doing With REGN - Benzinga
Regeneron Pharmaceuticals (NASDAQ:REGN) Coverage Initiated at Wolfe Research - MarketBeat
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease - Benzinga
Regeneron, Sanofi say resubmitted application to expand Dupixent label accepted in U.S. - Seeking Alpha
ING Groep NV Grows Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
FDA to review Sanofi, Regeneron’s Dupixent sBLA for CSU - Pharmaceutical Business Review
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Upgraded by Citigroup - MarketBeat
Regeneron, Sanofi Get New FDA Review of Dupixent for CSU - MarketWatch
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria - GlobeNewswire
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous - The Bakersfield Californian
리제네론 파마슈티컬스 (REGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.34%
0.09%
자본화:
|
볼륨(24시간):